immunogen
candidateinactiv
vaccin
prepar
sarscov
strain
evalu
balbc
mice
potent
humor
immun
respons
induc
elicit
three
time
immun
interv
vaccin
combin
three
type
adjuv
freund
adjuv
al
oh
adjuv
cpg
adjuv
titer
specif
igg
antibodi
three
test
group
peak
sixth
week
first
vaccin
signific
differ
exist
kinet
specif
igg
antibodi
level
strong
neutral
capac
exhibit
microcytopath
effect
neutral
test
indic
specif
antibodi
protect
western
blot
assay
demonstr
specif
induc
serum
antibodi
sever
acut
respiratori
syndrom
sar
first
sever
viral
epidem
encount
centuri
spread
countri
region
sever
threaten
worldwid
public
health
caus
agent
sar
confirm
formal
announc
novel
correspond
author
tel
fax
coronaviru
world
health
organ
april
establish
solid
base
us
effect
control
final
erad
diseas
sar
coronaviru
sarscov
novel
mut
highli
infecti
compar
known
coronavirus
genom
sequenc
differ
sarscov
isol
determin
import
structur
function
protein
unscrambl
first
outbreak
sar
control
worldwid
mani
thing
regard
nosogenesi
antigen
immuogen
sarscov
still
remain
unclear
specif
drug
develop
long
term
safe
effici
sar
vaccin
play
import
role
prevent
sar
possibl
futur
outbreak
present
studi
perform
object
determin
immunogen
candidateinactiv
sarscov
vaccin
made
strain
balbc
mice
sarscov
strain
ncbigenbank
isol
sampl
onset
sar
patient
guangdong
provinc
china
screen
vaccin
strain
vero
cell
cultiv
routin
mem
medium
contain
bovin
serum
follow
infect
strain
viru
cytopath
effect
cpe
reach
cell
suspens
frozen
thaw
three
time
store
c
titer
viru
suspens
measur
tcid
ml
largescal
cultiv
strain
viru
inactiv
treatment
formaldehyd
vv
h
inactiv
effici
antigen
inactiv
viru
strictli
identifi
centrifug
g
min
viru
supernat
collect
purifi
concentr
gel
permeat
chromatographi
immunogen
anim
immun
three
adjuv
employ
name
freund
adjuv
includ
freund
complet
adjuv
freund
incomplet
adjuv
sigma
cpg
adjuv
gml
provid
molecular
immunolog
institut
first
militari
medic
univers
china
al
oh
adjuv
selfprepar
mgml
equal
volum
adjuv
mix
prepar
immunogen
immun
balbc
mice
fed
group
neg
pressur
isol
mice
divid
three
test
group
accord
adjuv
group
immun
freund
adjuv
vaccin
n
group
b
al
oh
adjuv
vaccin
n
group
c
cpg
adjuv
vaccin
n
simultan
adjuv
control
inject
adjuv
alon
set
three
time
immun
given
interv
week
first
immun
perform
subcutan
dose
ml
viru
protein
concentr
mgml
mix
adjuv
mous
second
third
vaccin
carri
celiac
way
dose
ml
vaccin
third
immun
contain
adjuv
first
vaccin
batch
blood
sampl
collect
tail
bleed
initi
day
day
serum
separ
centrifug
g
min
store
c
microtit
plate
coat
inactiv
sarscov
dilut
contain
gml
total
viru
protein
overnight
c
block
bovin
serum
pbst
phosphatebuff
salin
contain
c
min
plate
wash
five
time
pbst
twofold
serial
serum
dilut
ad
lwell
incub
c
min
wash
plate
hrp
horseradish
peroxidas
conjug
antibodi
goat
antimous
igg
goat
antimous
igm
sinoamerican
biotech
ad
lwell
incub
c
min
wash
plate
pbst
opd
substrat
ophenylendiamin
sigma
ad
lwell
incub
c
min
reaction
stop
sulfur
acid
absorb
nm
measur
micropl
reader
biorad
model
assay
normal
serum
use
neg
control
posit
antiserum
includ
plate
interpl
variabl
control
antibodi
titer
defin
highest
dilut
serum
ratio
samplea
neg
control
greater
neutral
antibodi
titer
measur
accord
modifi
protocol
polio
antibodi
serum
sampl
dilut
twofold
serial
dilut
mem
mainten
medium
mix
equal
volum
tcid
activ
viru
incub
c
min
neutral
mixtur
success
ad
lwell
vero
cell
monolay
microtit
plate
well
normal
cell
control
ad
l
mainten
medium
well
viru
control
ad
unneutr
viru
instead
plate
incub
c
co
incub
cell
statu
monitor
sarscov
cpe
everi
h
well
viru
control
show
cpe
cell
control
remain
normal
neutral
antibodi
titer
defin
highest
dilut
serum
protect
cultur
cpe
photograph
taken
phasecontrast
microscop
western
blot
assay
carri
accord
protocol
molecular
clone
first
sarscov
protein
separ
sdspage
stack
polyacrylamid
gel
combin
separ
gel
miniapparatu
biorad
mini
protean
well
separ
protein
gel
transfer
nitrocellulos
membran
small
apparatu
biorad
mini
transblot
macm
current
h
block
bovin
serum
pbst
min
membran
incub
mous
antiserum
dilut
normal
serum
neg
control
min
room
temperatur
wash
pbst
membran
incub
hrpconjug
goat
antimous
igg
dilut
min
wash
dab
substrat
diaminobenzidin
sigma
ad
incub
brown
color
develop
convalesc
serum
sar
patient
use
posit
control
incub
hrpconjug
goat
antihuman
igg
antibodi
sinoamerican
biotech
igm
antibodi
level
five
set
mice
sera
first
month
measur
elisa
result
shown
fig
result
adjuv
control
neg
test
group
antisarscov
specif
igm
antibodi
induc
inactiv
vaccin
group
immun
freund
adjuv
vaccin
c
cpg
adjuv
vaccin
igm
antibodi
level
vari
regularli
reach
peak
point
went
hereaft
group
b
al
oh
adjuv
vaccin
igm
antibodi
titer
present
fluctuat
booster
immuniza
eleven
batch
mice
serum
sampl
detect
elisa
sampl
twofold
serial
dilut
hrpconjug
goat
antimous
igg
antibodi
opd
substrat
appli
specif
antibodi
titer
shown
reciproc
highest
serum
dilut
twofold
greater
neg
control
tion
show
posit
effect
rise
igm
antibodi
titer
eleven
batch
serum
sampl
measur
indirect
elisa
fig
specif
igg
antibodi
detect
one
week
first
immun
three
test
group
low
titer
stimul
second
immun
especi
third
one
igg
antibodi
level
increas
rapidli
peak
sixth
week
maximum
titer
group
freund
adjuv
vaccin
b
al
oh
adjuv
vaccin
four
eight
time
group
c
cpg
adjuv
vaccin
respect
stage
specif
igg
antibodi
titer
three
test
group
went
rel
steadi
level
two
set
mice
antisera
examin
sampl
collect
day
third
vaccin
day
third
vaccin
mice
group
immun
freund
adjuv
vaccin
result
shown
tabl
fig
serum
sampl
cpe
present
dilut
cpe
cpe
column
row
tabl
neutral
antibodi
titer
calcul
sampl
cpe
observ
dilut
cpe
cpe
column
row
tabl
neutral
titer
fig
display
neutral
photograph
h
antiserum
collect
group
compar
cell
control
fig
posit
control
show
mark
morpholog
chang
cpe
cell
infect
sarscov
becam
refractil
round
fig
neutral
test
activ
viru
first
neutral
serial
dilut
antiserum
ad
vero
cell
monolay
neutral
dilut
antiserum
cell
still
kept
normal
morpholog
charact
fig
uninfect
cell
neutral
dilut
cell
present
morpholog
chang
cpe
fig
antiserum
sampl
group
immun
freund
adjuv
vaccin
identifi
western
blot
separ
protein
inactiv
sarscov
suspens
show
two
domin
band
kda
sever
minor
band
gel
lane
fig
antiserum
interact
electrotransf
viru
antigen
protein
two
strong
band
show
nitrocellulos
membran
lane
fig
convalesc
serum
sar
patient
use
posit
control
also
show
two
similar
band
lane
fig
posit
reaction
detect
normal
serum
lane
fig
immunogen
evalu
essenti
work
develop
viral
inactiv
vaccin
sarscov
highli
infect
lethal
readi
immun
protocol
may
directli
employ
studi
sarscov
inactiv
treatment
formaldehyd
vv
h
antigen
well
preserv
three
time
immun
twoweek
interv
appli
result
show
sarscov
strain
inactiv
vaccin
could
induc
potent
humor
immun
respons
balbc
mice
studi
evalu
vaccin
rat
rabbit
hors
rhesu
monkey
result
shown
also
suggest
strong
immunogen
adjuv
may
play
activ
role
gener
mainten
immun
respons
freund
adjuv
commonli
use
anim
vaccin
al
oh
adjuv
safe
recommend
adjuv
human
vaccin
cpg
cpg
motif
new
immun
stimulatori
dna
sequenc
like
use
new
type
human
vaccin
adjuv
low
sideeffect
high
immun
potenc
studi
three
kind
adjuv
use
combin
inactiv
vaccin
mark
differ
exist
among
al
oh
adjuv
freund
adjuv
exhibit
stronger
stimulatori
efficaci
cpg
adjuv
neutral
capac
import
index
viral
vaccin
previou
experi
vaccin
may
elicit
high
level
neutral
antibodi
studi
high
titer
neutral
antibodi
induc
balbc
mice
neutral
test
cross
neutral
identifi
sarscov
strain
ncbigenbank
strain
ncbigenbank
dynam
variat
specif
antibodi
titer
fig
booster
immun
play
import
role
gener
high
level
specif
antibodi
notic
titer
decreas
follow
peak
point
thu
longev
protect
antibodi
need
determin
studi
base
potent
antigen
immunogen
sarscov
spike
kda
n
nucleocapsid
kda
membran
kda
protein
may
select
target
sar
vaccin
develop
present
studi
specif
serum
antibodi
induc
strain
inactiv
vaccin
identifi
western
blot
assay
two
domin
band
sever
minor
band
exhibit
gel
sdspage
electrophoresi
migrat
viru
protein
somewhat
block
visual
effect
arch
front
lane
fig
consid
imbal
migrat
rate
protein
marker
lane
fig
viru
protein
actual
molecular
weight
two
main
protein
band
littl
smaller
appar
valu
estim
kda
equival
n
protein
sarscov
respect
protein
detect
like
due
loss
longterm
storag
inactiv
sampl
treatment
togeth
rel
low
protein
content
follow
immunochem
reaction
antiserum
two
strong
band
exhibit
membran
lane
fig
exactli
correspond
posit
gel
wherea
color
band
gener
membran
normal
serum
lane
fig
convalesc
serum
sar
patient
use
posit
result
obtain
lane
fig
demonstr
specif
antibodi
induc
inactiv
vaccin
produc
strain
summari
studi
describ
safeti
immunogen
deactiv
sar
vaccin
test
model
result
indic
specif
igg
antibodi
produc
immun
inactiv
sarscov
vaccin
kinet
iggspecif
antibodi
shown
well
regular
antiserum
could
specif
neutral
sarscov
antibodi
sarscov
protein
n
appear
antiserum
western
blot
assay
result
provid
evid
inactiv
sar
vaccin
produc
specif
antibodi
implic
therapeut
applic
deactiv
sar
vaccin
